In contrast, in the low IL-6 group, 9 patients died due to tumor progression (32.1%), and 2 patients died from liver failure unrelated to tumor progression (7.1%), indicating a difference in the causes of death (Supplementary Table 9). This evidence concerns the gene IL6 and liver failure.